Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

Arthritis and Rheumatism

Volumn 56, Issue 11, 2007, Pages 3837-3846

  Gliddon, A E ^a   Dore C J ^b   Black, C M ^c   McHugh, N ^d   Moots, R ^e   Denton, C P ^c   Herrick, A ^f   Barnes, T ^e   Camilleri, J ^g   Chakravarty, K ^h   Emery, P ⁱ   Griffiths, B ^j   Hopkinson, N D ^k   Hickling, P ^l   Lanyon, P ^m   Laversuch, C ⁿ   Lawson, T ^o   Mallya, R ^p   Nisar, M ^q   Rhys Dillon, C ^r   Sheeran, T ^s   Maddison, P J ^t,u   more..

^a BANGOR UNIVERSITY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^e UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^h HAROLD WOOD HOSPITAL   (United Kingdom)

ⁱ CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^j FREEMAN HOSPITAL   (United Kingdom)

^k Christchurch Hospital   (United Kingdom)

^l DERRIFORD HOSPITAL   (United Kingdom)

^m QUEEN S MEDICAL CENTRE   (United Kingdom)

ⁿ TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^o PRINCESS OF WALES HOSPITAL   (United Kingdom)

^p WARRINGTON AND HALTON HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q QUEEN S HOSPITAL   (United Kingdom)

^r ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

^s ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^t YSBYTY GWYNEDD   (United Kingdom)

^u BANGOR UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; QUINAPRIL; TACROLIMUS; VASODILATOR AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SCLERODERMA; SHORT FORM 36; SIDE EFFECT; TREATMENT OUTCOME; ULCER; VISUAL DISORDER;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RAYNAUD DISEASE; SCLERODERMA, LIMITED; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 36049042221     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22965     Document Type: Article

References (37)

1. Black CM, Denton CP. Scleroderma and related disorders in adults and children. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. The Oxford textbook of rheumatology. 2nd ed. Oxford: Oxford University Press: 1998. p. 1217-47.
2. Silman AJ. Mortality from scleroderma in England and Wales 1968-1985. Ann Rheum Dis 1991;50:95-6.
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
4. Sjogren RW. Gastrointestinal motility disorders in scleroderma [review]. Arthritis Rheum 1994;37:1265-82.
5. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998;17:48-54.
6. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91, vi.
7. McGee BA, Barnett MD, Small RE. Current options for the treatment of systemic scleroderma. Clin Pharm 1991;10:14-25.
8. Nilsson H, Jonason T, Leppert J, Ringqvist I. The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm: a double-blind crossover study versus placebo. Acta Med Scand 1987;221:53-60.
9. Gjorup T, Kelbaek H, Hartling OJ, Nielsen SL. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J 1986;111:742-5.
10. Kallenberg CG, Wouda AA, Kuitert JJ, Tijssen J, Wesseling H. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects. J Rheumatol 1987;14:284-90.
11. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-55.
12. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
13. Challenor VF. Angiotensin converting enzyme inhibitors in Raynaud's phenomenon. Drugs 1994;48:864-7.
14. Aikimbaev KS, Oguz M, Ozbek S, Demirtas M, Birand A, Batyraliev T. Comparative assessment of the effects of vasodilators on peripheral vascular reactivity in patients with systemic scleroderma and Raynaud's phenomenon: color Doppler flow imaging study. Angiology 1996;47:475-80.
15. Madsen JL, Hvidt S. Raynaud's disease treated with captopril (Capoten): a randomized double-blind cross-over study. Ugeskr Laeger 1984;146:2695-7. In Danish.
16. Rustin MH, Almond NE, Beacham JA, Brooks RJ, Jones DP, Cooke ED, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol 1987;117:751-8.
17. Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ. Enalapril in Raynaud's phenomenon. J Clin Pharm Ther 1988;13:145-50.
18. Challenor VF, Waller DG, Hayward RA, Griffin MA, Roath OS. Subjective and objective assessment of enalapril in primary Raynaud's phenomenon. Br J Clin Pharmacol 1991;31:477-80.
19. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
20. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
21. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study [published erratum appears in Circulation 1996;94:1490]. Circulation 1996;94:258-65.
22. Scharti M, Boksch W, Dreysse S. Remodelling of myocardium and arteries by chronic angiotensin converting enzyme inhibition of hypertensive patients. J Hypertens 1994;12 Suppl 4:S37-42.
23. Hornig B, Arakawa N, Haussman D, Drexler H. ACE-inhibition with quinapril improves endothelial function in patients with chronic heart failure due to increased availability of nitric oxide: potential role of affinity to tissue ACE. Circulation 1997;96 Suppl 1:1671-2.
24. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990;336:1144-7.
25. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
26. Scott J, Huskisson EC. Accuracy of subjective measurements made with or without previous scores: an important source of error in serial measurement of subjective states. Ann Rheum Dis 1979;38:558-9.
27. Brennan P, Silman A, Black C, Bernstein R, Coppock J, Maddison P, et al, on behalf of the UK Scleroderma Study Group. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992;31:457-60.
28. Stata statistical software: release 9. College Station (TX): StataCorp; 2005.
29. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
30. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
31. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
32. Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH Jr, Steen VD, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis: review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983;62:335-52.
33. Lopez-Ovejero JA, Saal SD, D'Angelo WA, Cheigh JS, Stenzel KH, Laragh JH. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979;300:1417-9.
34. Takabatake N, Arao T, Sata M, Abe S, Inoue S, Shibata Y, et al. Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy. Eur J Nucl Med Mol Imaging 2005;32:221-8.
35. Abraham MR, Olson LJ, Joyner MJ, Turner ST, Beck KC, Johnson BD. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation 2002;106:1794-9.
36. Lefebvre F, Prefontaine A, Calderone A, Caron A, Jasmin JF, Villenueve L, et al. Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond) 2006;111:217-24.
37. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006;6:271-6.